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MAJOR ARTICLE

Molecular Epidemiology of Infant Botulism in
California and Elsewhere, 1976–2010
Haydee A. Dabritz,1,a Karen K. Hill,2 Jason R. Barash,1 Lawrence O. Ticknor,3 Charles H. Helma,2 Nir Dover,1
Jessica R. Payne,1 and Stephen S. Arnon1
1
Infant Botulism Treatment and Prevention Program, Division of Communicable Disease Control, Center for Infectious Diseases, California Department of
Public Health, Richmond, California; 2Bioscience Division, and 3Computing, Computational and Statistical Sciences Division, Los Alamos National
Laboratory, Los Alamos, New Mexico

Background. Infant botulism (IB), ﬁrst identiﬁed in California in 1976, results from Clostridium botulinum
spores that germinate, multiply, and produce botulinum neurotoxin (BoNT) in the immature intestine. From
1976 to 2010 we created an archive of 1090 BoNT-producing isolates consisting of 1012 IB patient (10 outpatient,
985 hospitalized, 17 sudden death), 25 food, 18 dust/soils, and 35 other strains.
Methods. The mouse neutralization assay determined isolate toxin type (56% BoNT/A, 32% BoNT/B). Ampliﬁed fragment-length polymorphism (AFLP) analysis of the isolates was combined with epidemiologic information.
Results. The AFLP dendrogram, the largest to date, contained 154 clades; 52% of isolates clustered in just 2
clades, 1 BoNT/A (n = 418) and 1 BoNT/B (n = 145). These clades constituted an endemic C. botulinum population
that produced the entire clinical spectrum of IB. Isolates from the patient’s home environment (dust/soil, honey)
usually located to the same AFLP clade as the patient’s isolate, thereby identifying the likely source of infective spores.
C. botulinum A(B) strains were identiﬁed in California for the ﬁrst time.
Conclusions. Combining molecular methods and epidemiological data created an effective tool that yielded
novel insights into the genetic diversity of C. botulinum and the clinical spectrum, occurrence, and distribution
of IB in California.
Keywords. botulinum toxin; clinical spectrum; Clostridium baratii; Clostridium botulinum; Clostridium
butyricum; honey; infant botulism; molecular epidemiology; sudden infant death.

Infant botulism (IB) results when swallowed spores of
Clostridium botulinum (or rarely, neurotoxigenic C. butyricum or C. baratii) germinate, multiply, and produce
botulinum neurotoxin (BoNT) in the large intestine.
BoNT, the most poisonous substance known, causes
constipation, bulbar palsies, and ﬂaccid paralysis in infants by blocking acetylcholine release at the neuromuscular junction [1]. Approximately 20–50 IB cases occur
annually in California, more than in any other state.
Since initial identiﬁcation of IB in California in 1976
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[2–4], the California Department of Public Health Infant Botulism Treatment and Prevention Program has
archived patient epidemiological information and
C. botulinum strains isolated from patients’ feces and
their home environments.
Seven botulinum toxin types (A–G) are currently
known (an eighth was recently recognized [5, 6]); bont
gene sequencing has identiﬁed toxin subtypes or variants [7–10] (eg, A1, A2). Although most isolates produce a single toxin type, dual-toxin-producing strains
(Ab, Af, Ba, Bf, Bh) [5, 11–14] and type A strains with
an unexpressed bont/B gene, denoted A(B), exist [15–
17]. Neurotoxigenic C. butyricum produces BoNT/E,
while neurotoxigenic C. baratii produces BoNT/F
[18, 19].
Because the BoNT gene (bont) cluster is associated
with mobile genetic elements, the BoNT-producing
clostridia exhibit substantial genomic diversity, identiﬁable by various molecular techniques (reviewed in [10]).
We utilized ampliﬁed fragment-length polymorphism
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(AFLP) analysis for this study because of its robustness and
suitability for examining large collections of C. botulinum isolates [7, 20, 21], together with real-time polymerase chain reaction (RT-PCR) to identify bont subtypes, and combined the
molecular results with epidemiologic and clinical information.
This combination provided novel and unexpected insights into
both the bacterium and the occurrence of IB in California and
other parts of North America in the past 35 years.
METHODS
Case Deﬁnition, Case Identiﬁcation, and Collection of
Epidemiologic Data

An IB case was deﬁned as an infant with symptoms consistent
with the known paralyzing action of BoNT, including sudden
death, in which BoNT or C. botulinum was identiﬁed in intestinal
contents or feces. Cases outside of California were identiﬁed
through distribution of Human Botulism Immune Globulin Intravenous (BIG-IV; BabyBIG [1]) and had C. botulinum freshly
isolated from a second fecal specimen or were identiﬁed through
the Centers for Disease Control and Prevention (CDC) national
surveillance reports (http://www.cdc.gov/nationalsurveillance/
botulism-surveillance.html). Cases were assigned to the state
and county in which the infant lived for the 2 weeks immediately
before onset (deﬁned as the date on which the parent ﬁrst
contacted a medical provider about the symptoms of the illness).
The incidence calculations included all US IB cases from 1976
to 2010 and live-births in California by county and nationwide
by state, available from the California Department of Public
Health (CDPH) at http://www.cdph.ca.gov/data/statistics/Pages/
StatewideBirthStatisticalDataTables.aspx (accessed November
21, 2011) and from the National Center for Health Statistics, Hyattsville, MD, at http://www.cdc.gov/nchs/births.htm (accessed
December 8, 2011), respectively. Epidemiological data for all California and BIG-IV-treated patients elsewhere were obtained by
home visit and/or telephone interview.
Culture and DNA Isolation

Clostridium botulinum was originally isolated from patient and
environmental specimens using standard methods [22], frozen
at −70°C, and then freshly cultured to create cell pellets for
DNA isolation (see online Supplementary Data) that followed
the protocol for DNA extraction from Gram-positive bacteria
using the Qiagen DNeasy Blood and Tissue Kit.
AFLP Analysis

For AFLP analysis, DNA preparations were digested with 2 restriction enzymes selected for A/T-rich genomes, linkers were
ligated to the resulting fragments, and a series of PCR ampliﬁcations were performed as previously described [7]. Forty DNA
fragment sizes were used to create a genetic ﬁngerprint representing each isolate [23]. Clustering analysis of the fragment sizes for
2
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the 1091 isolates created a dendrogram with 154 clades. (The nontoxigenic C. sporogenes ATCC 11437 isolate was part of the collection.) Differences of >0.20 genetic distance units, the error
inherent to the method, differentiated the clades from each
other. (See online Supplementary Data for details.)
Toxin Gene Characterization by RT-PCR

Six hundred thirty-ﬁve type A and type B isolates, 58% of the
collection, were characterized by RT-PCR to determine the subtype and presence of an unexpressed (“silent”) bont/B gene (see
online Supplementary Data for primers, probes, and conditions
used).
Spatial Analysis

Latitude and longitude coordinates were assigned to the patient’s residence address at onset of illness, with ZIP code or
city centroid coordinates assigned for nonmatching or missing
addresses. For clades with ≥10 isolates, SaTScan (http://www.
satscan.org) with a case-control model was used to search for
geographic or geographic-temporal clusters within that clade
by comparing its IB patient isolates to those of all other California IB patients [24]. Environmental, food, and sudden-death
case isolates were excluded from this analysis. Possible geographic-temporal clusters were sought in circular geographic
areas of radius ≤125 km and maximum time windows of ≤5
years (see online Supplementary Data for details).
RESULTS
Infant Botulism Occurrence in California and Elsewhere

From 1976 to 2010, 2803 IB cases were reported in the United
States; 1093 (39%) occurred in California. Table 1 lists the origins of the 1091 isolates studied. These 1091 isolates included
1012 IB patient isolates: 948 California, 55 other US states,
and 9 other countries. These 1012 IB patients included the entire clinical spectrum of IB (ie, 10 outpatient, 985 hospitalized,
and 17 sudden-death cases). An additional 79 patient-associated
environmental isolates and reference strains were also analyzed.
By the mouse neutralization assay, the 1090 neurotoxigenic isolates consisted of 609 (56%) BoNT/A; 345 (32%) BoNT/B; 22
(2%) bivalent BoNT/Af, /Ba, or /Bf; 11 (1%) BoNT/E; 9 (1%)
BoNT/F; and 8 (1%) BoNT/C, /D or /G. Eighty-six (8%) strains
were A(B) (Table 1).
The distribution of IB cases in California reﬂected the underlying population, with IB cases generally occurring in or near
large population centers in the Los Angeles basin, San Francisco
Bay area, and metropolitan San Diego (Figure 1A–D). However,
cases also occurred in less populated rural areas. More than half
of California IB cases were caused by BoNT/A strains and approximately one-third by BoNT/B strains. In comparison, bivalent and C. baratii BoNT/F strains were rare. IB incidence from
1976 to 2010 was 6.2/100 000 live-births, almost 3-fold higher

Table 1.

Source and Geographic Origin of Clostridial Isolates in the AFLP-Based Dendrogram (n = 1091)

Source
a

Infant botulism
Honey
Other foods

California

United States
(Outside California)

International
(Outside United States)

Unknown

Total

948
13

55
...

9
...

...
...

1012
13

2

7

3

...

12

Environmental
Foodborne botulism

14b
2

2
...

2
...

...
...

18
2

Wound botulism

12

3

...

...

15

Intestinal toxemia
Reference strainsc

1
...

1
5

2
6

...
4

4
15

Total

992

73

22

4

1091

Abbreviations: AFLP, amplified fragment-length polymorphism; BoNT, botulinum neurotoxin.
a

Includes 10 outpatient and 17 sudden-death cases.

b

n = 11 soil, n = 2 vacuum cleaner dust, and n = 1 ceiling fan dust; isolates collected from California IB patient homes.

Includes reference strain C. sporogenes ATCC11 437. Note that the bottom 4 rows of the table consist of 35 BoNT-producing isolates and 1 nontoxigenic C.
sporogenes strain.
c

than the nationwide incidence of 2.1/100 000 live-births in the
same interval. The annual ratio of BoNT/A to BoNT/B cases in
California over the 35-year study was 1.7 (range, 0.7–8.5).
AFLP Analysis and bont RT-PCR Characterization

The AFLP dendrogram differentiated the 1091 clostridial isolates into 154 clades, 64 with multiple isolates and 90 with only
a single isolate (Figure 2; Supplementary Data Appendix I).
A striking feature of the dendrogram was its 2 largest clades,
1 containing 418 BoNT/A isolates (n = 387 California IB
patients, Figure 1B) and the other containing 145 BoNT/B isolates (n = 141 California IB patients, Figure 1D). Hence, these 2
clades contained more than half (563; 52%) of all the isolates in
the collection and represented the 2 predominant genotypes of
C. botulinum that have caused IB in California for the past 35
years. The other 528 isolates of the collection located to the 152
other clades within the dendrogram.
The bont gene RT-PCR characterization identiﬁed subtypes/
variants bont/A1, /A2, /A4, and bont/B1, /B2, /B3, /B4, /B5, and
silent B (Figure 2). The Loch Maree BoNT/A3 strain, the only
BoNT/A3 isolate in the collection, was included for reference
purposes [25, 26]. The 86 A(B) isolates containing the unexpressed bont/(B) gene located to 14 clades; 67 isolates were
from California IB patients (Figure 3A). Also, a large number
of bivalent BoNT/Ba (n = 17), and /Bf (n = 3) and C. baratii
type F (n = 2) isolates were obtained from infant botulism
cases that occurred in different years and geographic locations
in California (Figure 3C).
Isolates From Outpatient and Sudden-Death Cases

The clinical spectrum of IB includes outpatient, hospitalized,
and fulminant (ie, sudden-death) cases [27, 28]. Ten IB outpatient isolates located to 5 clades: 4 to the largest BoNT/A clade,

3 to a closely related BoNT/A clade, 1 to the largest BoNT/B
clade, 1 to the largest A(B) clade, and 1 to a small BoNT/A
clade. Twelve of the 17 sudden-death cases located to the largest
BoNT/A clade and 1 to the largest BoNT/B clade (Figure 2; Supplementary Data Appendix I). Hence, both the largest BoNT/A
and the largest BoNT/B clades contained C. botulinum isolates
indistinguishable by AFLP analysis that produced the entire
clinical spectrum of infant botulism.
Clades Associated With Honey Consumption

The AFLP analysis produced 2 clades that contained isolates
both from honeys and from IB patients fed those honeys before
onset of illness. The ﬁrst clade contained 5 BoNT/A2 isolates
from 4 patients (1982, 1995, 1997, 2001) and from 1 commercial
honey consumed by the 1982 patient. The honeys fed to the other
3 patients were not available for testing. The second clade associated with honey consumption contained 18 patient and 8 honey
type B isolates from 1983 to 1988 (Table 2). All 26 isolates were
subtyped and determined to be bont/B5. Fourteen (78%) of the 18
patients had been fed honey in the month before onset of illness,
and 7 of the 8 honey isolates in this clade were from honeys consumed by 6 of the patients. One patient without a history of honey
consumption lived in the honey-producing area.
Clades Associated With Dust and Soils Collected at Patients’
Homes

Clostridium botulinum was isolated from 14 environmental
samples from the homes of 8 IB patients (Table 1, footnote
b), of which 11 located to the same clade as the patient’s isolate.
The co-location of patient and environmental isolate(s) in the
same clade included: 1 vacuum cleaner dust and 2 soil isolates
from the home of 2 sibling type A patients in an Alameda
County city; 1 vacuum cleaner dust and 2 soil isolates from
Infant Botulism—Molecular Epidemiology
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Figure 1. Infant botulism cases caused by C. botulinum types A and B in California, 1976–2010. A, All BoNT/A IB patient isolates (n = 560), excluding
A(B) isolates. B, Isolates in the largest AFLP BoNT/A clade, which contained a type A Hall strain, 383 California hospitalized IB cases, 4 outpatient cases,
and 12 sudden-death cases (not included on map). Note that cases occurred in all 35 years of the study period. A geographic but not temporal cluster of
radius 35 km was detected near Escondido (San Diego County). C, All BoNT/B IB patient isolates (n = 282). D, The largest AFLP BoNT/B clade (n = 141). Note
that cases occurred in all years of the study period except for 1979, 1992, 1993, and 2008. One geographic but not temporal cluster was identiﬁed in the Los
Angeles area near Anaheim (radius 39 km). Geographic-temporal clustering was determined using the Kulldorff spatial-scan statistic with a case-control
model [24]. Abbreviations: AFLP, ampliﬁed fragment-length polymorphism; BoNT, botulinum neurotoxin; IB, infant botulism.
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Figure 2. Schematic diagram of the AFLP dendrogram of 1091 clostridial isolates. Note that more than half the isolates (52%) located to just 2 large
clades, 1 of toxin type A and the other of toxin type B. Note also the wide separation of the 2 major A(B)-containing clades, the bivalent (BoNT/Ba- and /Bfcontaining) clades and other BoNT/A- and /B-containing clades. Dendrogram constructed using 40 DNA fragments and a cluster algorithm with the Jaccard
distance measure [23]. The full Figure 2 in pdf format may be found in Supplementary Data Appendix I; when the isolates in it are displayed in an 8-point
font, the ﬁgure measures approximately 4.5 m in length. Abbreviations: AFLP, ampliﬁed fragment-length polymorphism; BoNT, botulinum neurotoxin.
Infant Botulism—Molecular Epidemiology
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Figure 3. Occurrence and distribution of A(B), bivalent (Ba, Bf) and rare strains of C. botulinum. A, All A(B) California IB patient isolates (n = 66) located to
6 multimember and 5 singleton clades. One California 3-year-old intestinal toxemia patient isolate and 2 WB isolates not depicted. B, The second-largest
A(B) clade (n = 23) included 20 California patients and contained a geographic-temporal cluster of 3 patients near Bakersﬁeld. C, BoNT/Ba (n = 17), BoNT/Bf
(n = 3) and C. baratii type F (n = 2) California IB patient isolates. D, Clade of 12 BoNT/B, /Ba and /Bf patient isolates. Geographic-temporal clusters determined using the Kulldorff spatial-scan statistic [24]. Abbreviations: BoNT, botulinum neurotoxin; IB, infant botulism; WB, wound botulism.
6

•

JID

•

Dabritz et al

Table 2.

Descriptive Features of the Largest Clades (≥10 Isolates) Identiﬁed by AFLP Analysis
Number and Source of Isolates
IB Isolates
From Outside
CA

Figure/Panel
Where
Mapped

Years
Isolated

1. Largest BoNT/A

1/B

1976–2010

399d

5

3

3

5

3

2. Southern California A closely
related to above largest BoNT/A
3. Northern California A closely
related to above largest BoNT/A

N/A

1987–2007

12

...

...

...

...

...

N/A

1977–2010

66e

1

3

...

...

...

4. Northern California BoNT/A

4/A

1977–2010

23

...

5

...

...

...

5. Largest A(B)
6. Central Valley A(B)

N/A
3/B

1977–2010
1979–2010

31
20

9
3

...
...

...
...

2
...

1
...

7. Largest BoNT/B

1/D

1976–2010

142f

1

2

...

...

...

8. Primarily Southern California
BoNT/B closely related to the
above largest BoNT/B clade

N/A

1980–2001

12

...

...

...

...

...

9. East San Francisco Bay area
BoNT/B

4/B

1978–2009

10

...

1

...

...

...

10. Primarily 1992–1994 BoNT/B

4/C

1992–1999

30g

...

...

...

...

...

11. Southern California BoNT/B
12. Primarily 2000s BoNT/B

N/A
4/D

1983–1988
2008–2009i

18
10

...
...

...
...

8h
...

...
1

...
...

AFLP Clade in Figure 2a

CA IB
Isolates

Environmentalb

Food/
Honeyb

WB

Reference
Strainsc

13. BoNT/B, BoNT/Ba, BoNT/Bf

3/D

1978–2004

12

...

...

...

...

...

14. Primarily Mid-Atlantic BoNT/B

N/A

2005–2010

1

10

...

...

...

...

Abbreviations: AFLP, amplified fragment-length polymorphism; BoNT, botulinum neurotoxin; CA, California; IB, infant botulism; N/A, not applicable; WB, wound
botulism.
a

Geographical coordinates of patient isolate clusters within these clades may be found in Table 3.

b

Isolates associated with CA IB patients.

c

Reference strains that locate to the largest BoNT/A clade: Hall strain; 62A (Nevada cow liver 1921 [29]); California carrot 2006 [30]. Reference strains that located to
the largest A(B) clade: NCTC 2916 Colorado yellow corn 1929 [16].

d

Includes 4 outpatient (shown) and 12 sudden-death cases (not shown) in Figure 1B.

e

Includes 3 outpatient and 3 sudden-death cases.

f

Includes 1 sudden-death case not shown in Figure 1D.

g

All but 1 case occurred in 1992–1994.

h

Includes 1 isolate from a honey producer in Tulare County.

i

Nine of 10 IB cases occurred in 2008–2009. In 1986, the tenth case traveled from San Diego County to the San Francisco Bay area through the Los Angeles basin
(center of the 2008–2009 geographic cluster) within 2 weeks of onset of illness. The WB case (not shown in Figure 4D) occurred in 1999 in Santa Clara County.

the Sierra Nevada foothills home of a Madera County type A
patient; type A soil isolates from the homes of type A patients
in Ontario, California, and Reno, Nevada; and 1 type B soil isolate and 1 ceiling fan dust type B isolate from the home of 2 type
B twin patients in Stanislaus County. The 3 exceptions to the
clade co-location of patient and environmental isolates consisted of a type A soil isolate and a type B soil isolate from the Alameda County home of the 2 type A sibling patients and 2 type
A soil isolates from the homes of 2 Yolo County type A patients.
The Largest BoNT/A Clade

This clade contained 418 isolates from 399 California IB patients (Table 2, #1; Figure 1B), 1 IB patient from Mexico, 4 IB
patients from neighboring western states (Idaho, Nevada, Utah,
Washington), 5 wound botulism (WB) patients (n = 4 California, n = 1 Utah), 3 honeys, 2 food items (carrots, cow’s liver),

3 soil isolates associated with patients (n = 2 California, n = 1
Nevada), and a Hall strain. All 12 isolates subtyped were
bont/A1. Notably, no isolates in this clade were from states
east of the Rocky Mountains.
Geospatial analysis of the 387 California IB patient isolates
(excluding the 12 sudden-death cases) in this clade identiﬁed
a geographic cluster centered near Escondido (San Diego County) that contained 27 IB cases (radius approximately 35 km;
P = .005) (Figure 1B). Two other closely related BoNT/A clades
(Table 2, #2–3) also contained geographic clusters: 1 clade
(n = 12) contained a cluster of 7 isolates centered near Rialto
(San Bernardino County) (radius approximately 15 km;
P < .001), and the other clade (n = 70) contained a cluster of
48 isolates (76% of the clade’s IB cases) centered near Napa,
north of San Francisco Bay (radius approximately 124 km;
P < .001).
Infant Botulism—Molecular Epidemiology
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Table 3.

Geographical Coordinates of Patient Isolate Clusters
Figure/Panel
Where
Mapped

Cluster Center,
Lat/Long

1. Largest BoNT/A

1/B

33.12, −117.06

2. Southern California A closely
related to above largest BoNT/A

N/A

34.11, −117.38

3. Northern California A closely
related to above largest BoNT/A
4. Northern California BoNT/A

N/A

38.31, −122.32

4/A

38.63, −121.22

5. Largest A(B)

N/A

None

6. Central Valley A(B)
7. Largest BoNT/B

3/B
1/D

35.32, −119.09
33.83, −117.98

8. Primarily Southern California
BoNT/B closely related to the
largest BoNT/B clade
9. East San Francisco Bay area
BoNT/B

N/A

34.16, −118.13

4/B

37.73, −121.44

10. Primarily 1992–1994 BoNT/B
11. Southern California BoNT/B

4/C
N/A

34.29, −188.49
34.06, −118.43

12. Primarily 2000s BoNT/B

4/D

34.43, −118.47

13. BoNT/B, BoNT/Ba, BoNT/Bf
14. Primarily Mid-Atlantic BoNT/B

3/D
N/A

None
ND

AFLP Clade in Figure 2

Abbreviations: AFLP, amplified fragment-length polymorphism; BoNT,
botulinum neurotoxin; Lat/Long, latitude/longitude; N/A, not applicable; ND,
not determined.

The Largest BoNT/B Clade

This clade (Table 2, #7; Figure 1D) contained 145 isolates, 142
of which were from California IB patients, including 1 outpatient and 1 sudden-death case. The single strain in the clade
not from California was isolated in 1979 from the ﬁrst-recognized IB patient in the Czech Republic [31]. All 6 isolates subtyped were bont/B1. This clade contained a geographic cluster
in Southern California centered near Anaheim (Los Angeles
County) (radius approximately 39 km; P = .001) that contained
71 (50%) of the clade’s California IB patients.

had no geographic clusters in California, whereas the secondlargest A(B) clade (Table 2, #6) contained a geographic-temporal cluster from 2006 to 2009 centered in California’s Central
Valley near Bakersﬁeld (Kern County) (radius approximately
8 km; P = .047) that contained 3 IB cases (Figure 3B).
Bivalent (Ba, Bf ) Clades

The molecular analysis identiﬁed 17 bivalent B5a4 isolates that
located to 5 clades and 4 B5f isolates, 3 from California and 1
from Texas, that located to 3 clades. The largest of the bivalent
clades (Table 2, #13) notably contained several B5 and B5a4
isolates and 1 B5f isolate (Figure 3D). A single unique strain
that contained a bont/A5 gene and a partial bont/B gene [the
bont/A5(B3′) gene arrangement [9]] that was isolated from a
San Diego County IB patient located to a singleton clade.
Mid-Atlantic US Type B Clades

Two clades of BoNT/B patient isolates mapped mainly to certain areas in the eastern Mid-Atlantic United States. The ﬁrst
clade (n = 8) included the 1939 Tennessee BoNT/B1 Okra reference strain [32], 3 patients from Maryland, and 1 patient each
from New Jersey, Pennsylvania, Alabama, and California. The
California IB patient was born prematurely and had not been
discharged from her birth hospitalization before onset of illness.
However, some of the specialty formulas fed to her were produced in the Mid-Atlantic region; although these formulas tested negative for C. botulinum, 1 contained C. sporogenes. The
second Mid-Atlantic BoNT/B clade (Table 2, #14) contained
11 bont/B1 isolates: 8 IB patients from either New Jersey,
New York, or Pennsylvania; 1 patient from Colorado; and 2
patients from California and Oregon who had traveled to
New York City and Pennsylvania, respectively, in the month before onset of illness. Geographical clustering in these clades
could not be evaluated because the reference set of East Coast
patient isolates was too small.
Other Noteworthy California Clades

A(B) Strain Clades

The analysis identiﬁed 86 C. botulinum A(B) isolates (66 from
California IB patients and 14 from IB patients in Alaska, Arkansas, Colorado, Georgia, Illinois, Nevada, New Mexico, Oklahoma, Texas, Washington, and Wyoming). Such A(B) strains were
not previously known to exist in California (Table 2, #6; Figure 3A). The A(B) isolates located to 14 clades (7 multimember
clades and 7 singleton clades); 5 clades contained non-California
A(B) strains, and 2 contained both A(B) and type B strains.
A(B) strains were isolated in California in all years of the
study period except 1976, 1978, 1983, and 1995 (Figure 3A).
The largest A(B) clade (n = 43) contained isolates from 31 California IB patients, 8 other US IB patients, 1 Canada IB patient,
2 California WB patients and the National Collection of Type
Cultures reference strain NCTC 2916 (Table 2, #5). This clade
8
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Five additional California clades demonstrated either geographic or geographic-temporal clustering. A BoNT/A clade with 23
California IB patient and 5 environmental isolates (Table 2, #4;
Figure 4A) had a geographic-temporal cluster of 7 patients from
2005 to 2008 centered northeast of Sacramento (radius approximately 101 km; P = .003).
The second clade, BoNT/B with 10 IB patient and 1 soil isolate (Table 2, #9; Figure 4B), had a geographical cluster of 9 patient isolates that centered east of San Francisco Bay (radius of
approximately 69 km; P = .002). The third clade, BoNT/B with
30 California IB patient isolates, contained a geographic-temporal cluster from 1992 to 1994 in southern California with 18 patient isolates centered in the San Fernando Valley (Los Angeles
County) (radius approximately 97 km; P < .001) (Table 2, #10;
Figure 4C). The fourth clade of 12 BoNT/B California patients

Figure 4. Geographic and geographic-temporal clusters of California IB cases between 1976 and 2010. A, BoNT/A clade of 23 patient isolates with a
geographic-temporal cluster centered near Sacramento. This clade also contained 1 vacuum cleaner dust and 2 soil isolates (not shown). B, BoNT/B clade of
10 California patient isolates that clustered in the east San Francisco Bay area. The sole outlier patient lived in a central coastal county, had not traveled,
and had been fed nonsterile solid foods. This BoNT/B clade also contained 1 soil isolate (not shown) from a patient home in an eastern San Francisco Bay
city. C, BoNT/B clade of 30 California patient isolates with a geographic-temporal cluster that occurred in southern California, 1992–1994. Note the absence
of this particular C. botulinum type B strain in California patients before 1992 and after 1999, with 97% of the cases in the clade having occurred in the 4
years 1992–1994. D, BoNT/B clade of 10 California IB patient isolates with a geographic-temporal cluster in southern California (1 WB patient from 1999
not shown). All IB cases occurred in 2008–2009 except for the 1986 case, who was driven through the Los Angeles basin (center of cluster) 2 weeks before
onset of illness when the family moved from San Diego County to the San Francisco Bay area. Geographic-temporal clusters were determined using the
Kulldorff spatial-scan statistic [24]. Abbreviations: BoNT, botulinum neurotoxin; IB, infant botulism; WB, wound botulism.
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that also clustered in southern California both temporally
(1980–1983) and geographically was centered near Pasadena
(radius approximately 30 km; P = .015) (Table 2, #8).
The ﬁfth clade, BoNT/B with 10 IB and 1 WB patient isolates
(Table 2, #12; Figure 4D), contained a 2008–2009 geographictemporal cluster of 6 patient isolates centered in the Santa
Clarita Valley (Los Angeles County) (radius approximately
68 km; P < .001). Nine of 10 IB patients in this clade became
ill in 2008–2009; in 1986, the tenth patient became ill 2 weeks
after traveling through the Los Angeles basin (the center of the
cluster).
DISCUSSION
The Infant Botulism Treatment and Prevention Program
(IBTPP) collection of neurotoxigenic clostridial strains provided a unique opportunity to combine molecular and epidemiological information to better understand IB in California.
Signiﬁcant novel ﬁndings of this endeavor included: (1) the
identiﬁcation of 2 large clades that contained endemic strains
that caused more than half of the BoNT/A and more than
one-third of the BoNT/B IB cases in California in the 35-year
study period; (2) the co-location of patient isolates from all 3
segments of the IB clinical spectrum (outpatient, hospitalized,
sudden death) to the same BoNT/A or BoNT/B clade; (3) the
identiﬁcation of C. botulinum A(B) isolates in IB patients
from California and 11 other US states that would not have
been identiﬁed by the mouse neutralization assay; (4) the identiﬁcation of rare strains isolated from 25 IB and 2 adult botulism
cases that include BoNT/B5a4 (n = 17), BoNT/Bf (n = 4), and C.
baratii BoNT/F (n = 6) isolates; (5) the recognition of clades
whose isolates share a common-source origin (eg, honey); (6)
the identiﬁcation of clades whose isolates are restricted geographically to limited areas of California; and (7) the co-location to the same clade of C. botulinum patient and associated
dust, soil, and honey isolates that could cause IB when swallowed by susceptible infants. The extensive branching of the
dendrogram displays and emphasizes the different genetic backgrounds of C. botulinum strains that express the same toxin
types.
Clostridium botulinum type A(B) isolates have been reported
from Alaska, Arizona, Colorado, Georgia, Illinois, Louisiana,
Nebraska, New Mexico, Pennsylvania, Puerto Rico, Wisconsin,
and West Virginia [29, 33–35]. In this study, A(B) isolates were
newly identiﬁed in IB patients from Arkansas, California, Nevada, Oklahoma, Texas, Washington, and Wyoming, further suggesting that A(B) strains are widespread throughout the United
States. The molecular analysis and mouse neutralization assay
also identiﬁed 17 bivalent BoNT/B5a4 and 3 BoNT/Bf isolates
that caused IB in California. Recognition of BoNT/B5a4 strains
outside of California that cause IB has occurred infrequently;
only the 1976 Texas [36–38] and 1999 Texas and 2006 Nevada
10
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patients reported in the CDC annual national botulism surveillance summaries were previously known.
The AFLP analysis also identiﬁed clades that contained isolates
associated with honey exposure or that contained geographictemporal clustering. The 4 patients in the only bont/A2 clade
were fed honey; the clade also contained a bont/A2 isolate
from a honey consumed by 1 of the patients. The BoNT/A2
subtype had previously been isolated only from Argentinian
soils and from IB patients in Argentina [39], Italy [33], and
Japan who were fed honey [40], as well as from a Brazilian
honey [40] and from honey [41] fed to a New Jersey patient
that may have contained blended imported Argentinian
honey. Because honey may harbor C. botulinum spores, all
major public health, pediatric, and honey-producing institutions have recommended that honey not be fed to infants [42].
Three clusters within California BoNT/B clades occurred in
limited time spans: 1 in 1992–1994 (Figure 4C), 1 in 2008–2009
(Figure 4D), and 1 in 1983–1985 (not shown). The latter occurred in a clade of monovalent BoNT/B5 isolates associated
with honey exposure; interestingly, no monovalent BoNT/B5producing isolates have been identiﬁed in California since
1988. No common-source exposures to a food or environmental
source were identiﬁed for the temporal clusters in the 2 other
BoNT/B clades. Possible sources of exposure to C. botulinum
spores include nonsterile infant foods (eg, powdered infant
formulas, dry cereals, herbal teas [43–45]), and anthropomorphic activities or weather phenomena that disrupt surface soil
[46, 47].
Geographical localization of isolates in some clades (Figures 1, 3, and 4) suggests that local soil and/or climatic conditions
may contribute to multiplication and subsequent dissemination
of C. botulinum spores. Notably, isolates from several patients
and their home environments (dust/soil, honey) located to
the same clade. Soil surveys in Argentina [48] and the United
States [49] have reported differing prevalences and BoNT
types in different geographic regions. In the United States,
BoNT/A strains predominate in soils west of the Mississippi
River, while BoNT/B strains predominate in soils east of the
Mississippi River; this regionalization matches the nationwide
distribution of IB patient toxin types [22]. Our geographictemporal analyses found that IB isolates from certain clades
concentrated in speciﬁc geographical areas; for example, a
BoNT/A clade northeast of Sacramento (Figure 4A), a BoNT/B
clade in the San Francisco Bay area (Figure 4B), and a BoNT/B
clade in the Santa Clarita Valley (Figure 4D). Two clades of
BoNT/B isolates from patients who resided primarily in the
Mid-Atlantic United States or had recently traveled there were
also identiﬁed. These examples suggest that IB may be acquired
from the local environment or while traveling in endemic areas.
In conclusion, the molecular analyses provided new and useful information for elucidating epidemiological relationships
and for differentiating C. botulinum isolates. The study resulted

in an AFLP dendrogram of 1091 isolates that displays the genetic and epidemiological complexity of neurotoxigenic clostridia
(Figure 2 and Supplementary Data Appendix I). Importantly,
the geographical clustering of isolates was identiﬁed by use of
patient epidemiological information. The combination of molecular methods and epidemiological data created an effective
tool that yielded novel insights into the genetic diversity of C.
botulinum and the clinical spectrum, occurrence, and distribution of IB in California.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases
online (http://jid.oxfordjournals.org). Supplementary materials consist of
data provided by the author that are published to beneﬁt the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes
Acknowledgments. We especially thank the many former IBTPP epidemiologists for carefully collecting IB patient information. We also thank
Theresa Smith, US Army Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, MD, for assistance in identifying the origins of certain
reference strains and USAMRIID for permission to compare the AFLP patterns of its C. botulinum strains to the AFLP patterns of IBTPP strains. The
Microbial Disease Laboratory, CDPH, isolated and generously provided the
12 California WB isolates. The type E reference strain K112 published by
Hyytiä et al in 1999 [50] was an earlier gift to CDPH from the Food Research
Institute, University of Wisconsin-Madison.
The ﬁndings and conclusions in this report are those of the authors and
do not necessarily represent the views of the Los Alamos National Laboratory or the California Department of Public Health.
Financial support. The RT-PCR assay development work was supported by the US Department of Homeland Security Science and Technology
Directorate. This work was otherwise supported by the Infant Botulism
Treatment and Prevention Fund of the California Department of Public
Health.
Potential conﬂicts of interest. All authors: No potential conﬂicts of
interest.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
1. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human
Botulism Immune Globulin for the treatment of infant botulism.
N Engl J Med 2006; 354:462–71.
2. Pickett J, Berg B, Chaplin E, Brunstetter-Shafer MA. Syndrome of botulism in infancy: clinical and electrophysiologic study. N Engl J Med
1976; 295:770–2.
3. Midura TF, Arnon SS. Infant botulism: identiﬁcation of Clostridium
botulinum and its toxins in faeces. Lancet 1976; 2:934–6.
4. Arnon SS, Midura T, Clay S, Wood R, Chin J. Infant botulism: epidemiological, clinical, and laboratory aspects. JAMA 1977; 237:1946–51.
5. Barash JR, Arnon SS. A novel strain of Clostridium botulinum that
produces type B and type H botulinum toxins. J Infect Dis 2014;
209:183–91.
6. Dover N, Barash JR, Hill KK, Xie G, Arnon SS. Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis 2014;
209:192–202.

7. Hill KK, Smith TJ, Helma CJ, et al. Genetic diversity among botulinum
neurotoxin–producing clostridial strains. J Bacteriol 2007; 189:818–32.
8. Jacobson MJ, Lin G, Raphael B, Andreadis J, Johnson EA. Analysis of
neurotoxin cluster genes in Clostridium botulinum strains producing
botulinum neurotoxin serotype A subtypes. Appl Environ Microbiol
2008; 74:2778–86.
9. Dover N, Barash JR, Arnon SS. Novel Clostridium botulinum toxin gene
arrangement with subtype A5 and partial subtype B3 botulinum neurotoxin genes. J Clin Microbiol 2009; 47:2349–50.
10. Hill KK, Smith TJ. Genetic diversity within Clostridium botulinum
serotypes, botulinum neurotoxin gene clusters and toxin subtypes.
Curr Top Microbiol Immunol 2013; 364:1–20.
11. Lúquez C, Raphael BH, Maslanka SE. Neurotoxin gene clusters in Clostridium botulinum type Ab strains. Appl Environ Microbiol 2009;
75:6094–101.
12. Fernández RA, Ciccarelli AS, Arenas GN, Giménez DF. First outbreak of
botulism caused by Clostridium botulinum subtype Af. [Spanish]. Rev
Argent Microbiol 1986; 18:29–31.
13. Giménez DF. Clostridium botulinum subtype Ba. Zentralbl Bakteriol
Mikrobiol Hyg A 1984; 257:68–72.
14. Hatheway CL, McCroskey LM. Examination of feces and serum for diagnosis of infant botulism in 336 patients. J Clin Microbiol 1987;
25:2334–8.
15. Franciosa G, Ferreira JL, Hatheway CL. Detection of type A, B, and E
botulism neurotoxin genes in Clostridium botulinum and other Clostridium species by PCR: evidence of unexpressed type B toxin genes
in type A toxigenic organisms. J Clin Microbiol 1994; 32:1911–7.
16. Henderson I, Whelan SM, Davis TO, Minton NP. Genetic characterisation of the botulinum toxin complex of Clostridium botulinum strain
NCTC 2916. FEMS Microbiol Lett 1996; 140:151–8.
17. Hutson RA, Zhou Y, Collins MD, Johnson EA, Hatheway CL, Sugiyama
H. Genetic characterization of Clostridium botulinum type A containing
silent type B neurotoxin gene sequences. J Biol Chem 1996; 271:
10786–92.
18. Aureli P, Fenicia L, Pasolini B, Gianfranceschi M, McCroskey LM,
Hatheway CL. Two cases of type E infant botulism caused by neurotoxigenic Clostridium butyricum in Italy. J Infect Dis 1986; 154:207–11.
19. Hall JD, McCroskey LM, Pincomb BJ, Hatheway CL. Isolation of an organism resembling Clostridium barati which produces type F botulinal
toxin from an infant with botulism. J Clin Microbiol 1985; 21:654–5.
20. Keto-Timonen R, Nevas M, Korkeala H. Efﬁcient DNA ﬁngerprinting
of Clostridium botulinum types A, B, E, and F by ampliﬁed fragment
length polymorphism analysis. Appl Environ Microbiol 2005;
71:1148–54.
21. Macdonald TE, Helma CH, Shou Y, et al. Analysis of Clostridium botulinum serotype E strains using multilocus sequence typing, ampliﬁed
fragment length polymorphism, and variable-number tandem-repeat
analysis and botulinum neurotoxin gene sequencing. Appl Environ Microbiol 2011; 77:8625–34.
22. Centers for Disease Control and Prevention. Botulism in the United
States, 1899–1996: handbook for epidemiologists, clinicians and laboratory workers. Atlanta, GA: U.S. Dept. of Health and Human Services,
1998.
23. Ticknor LO, Kolsto AB, Hill KK, et al. Fluorescent ampliﬁed fragment length polymorphism analysis of Norwegian Bacillus cereus and
Bacillus thuringiensis soil isolates. Appl Environ Microbiol 2007;
67:4863–73.
24. Kulldorff M. Bernoulli, discrete Poisson and continuous Poisson models: a spatial scan statistic. Comms Stat Theory Methods 1997;
26:1481–96.
25. Monro TK, Knox WWN. Remarks on botulism as seen in Scotland in
1922. Br Med J 1923; 1:279–81.
26. Leighton GR. Botulism and food preservation (the Loch Maree tragedy).
London: W. Collins and Sons, 1923.
27. Nevas M, Lindstrom M, Virtanen A, et al. Infant botulism acquired
from household dust presenting as sudden infant death syndrome.
J Clin Microbiol 2005; 43:511–3.

Infant Botulism—Molecular Epidemiology

•

JID

•

11

28. Arnon SS, Midura TF, Damus K, Wood RM, Chin J. Intestinal infection
and toxin production by Clostridium botulinum as one cause of sudden
infant death syndrome. Lancet 1978; 1:1273–7.
29. Raphael BH, Joseph LA, McCroskey LM, Lúquez C, Maslanka SE. Detection and differentiation of Clostridium botulinum type A strains
using a focused DNA microarray. Mol Cell Probes 2010; 24:146–53.
30. Sheth AN, Wiersma P, Atrubin D, et al. International outbreak of severe
botulism with prolonged toxemia caused by commercial carrot juice.
Clin Infect Dis 2008; 47:1245–51.
31. Neubauer M, Milácek V. Infant botulism type B in central Europe. Zentralbl Bakteriol Mikrobiol Hyg [A] 1981; 250:540–7.
32. Tucker CB, Swanson H. Outbreak of botulism in Tennessee due to Type
B Cl. botulinum. Public Health Rep 1939; 54:1556–60.
33. Franciosa G, Floridi F, Maugliani A, Aureli P. Differentiation of the gene
clusters encoding botulinum neurotoxin type A complexes in Clostridium botulinum type A, Ab, and A(B) strains. Appl Environ Microbiol
2004; 70:7192–9.
34. Kirma N, Ferreira JL, Baumstark BR. Characterization of six type A
strains of Clostridium botulinum that contain type B toxin gene sequences. FEMS Microbiol Lett 2004; 231:159–64.
35. Macdonald TE, Helma CH, Ticknor LO, et al. Differentiation of Clostridium botulinum serotype A strains using multiple-locus variablenumber tandem-repeat analysis. Appl Environ Microbiol 2008;
74:875–82.
36. Hatheway CL, McCroskey LM, Lombard GL, Dowell VR Jr. Atypical
toxin variant of Clostridium botulinum type B associated with infant
botulism. J Clin Microbiol 1981; 14:607–11.
37. Giménez DF, Giménez JA. Identiﬁcation of strain B 657 of Clostridium
botulinum. [in Spanish]. Rev Argent Microbiol 1983; 15:51–5.
38. Edmond BJ, Guerra FA, Blake J, Hempler S. Case of infant botulism in
Texas. Tex Med 1977; 73:85–8.
39. Sagua MD, Lúquez C, Barzola CP, Bianco MI, Fernández RA.
Phenotypic characterization of Clostridium botulinum strains isolated

12

•

JID

•

Dabritz et al

40.

41.

42.

43.
44.

45.

46.
47.
48.

49.
50.

from infant botulism cases in Argentina. Rev Argent Microbiol 2009;
41:141–7.
Umeda K, Seto Y, Kohda T, Mukamoto M, Kozaki S. A novel multiplex
PCR method for Clostridium botulinum neurotoxin type A gene cluster
typing. Microbiol Immunol 2010; 54:308–12.
Johnson EA, Tepp WH, Bradshaw M, Gilbert RJ, Cook PE, McIntosh
ED. Characterization of Clostridium botulinum strains associated with
an infant botulism case in the United Kingdom. J Clin Microbiol 2005;
43:2602–7.
Arnon SS, Midura TF, Damus K, Thompson B, Wood RM, Chin J.
Honey and other environmental risk factors for infant botulism. J Pediatr 1979; 94:331–6.
Kautter DA, Lilly T Jr, Solomon HM, Lynt RK. Clostridium botulinum
spores in infant foods: a survey. J Food Prot 1982; 45:1028–9.
Bianco MI, Lúquez C, de Jong LI, Fernández RA. Presence of Clostridium
botulinum spores in Matricaria chamomilla (chamomile) and its relationship with infant botulism. Int J Food Microbiol 2007; 121:357–60.
Brett MM, McLauchlin J, Harris A, et al. A case of infant botulism with
a possible link to infant formula milk powder: evidence for the presence
of more than one strain of Clostridium botulinum in clinical specimens
and food. J Med Microbiol 2005; 54(Pt 8):769–76.
Long SS. Epidemiologic study of infant botulism in Pennsylvania: report
of the Infant Botulism Study Group. Pediatrics 1985; 75:928–34.
Flynn NM, Hoeprich PD, Kawachi MM, et al. An unusual outbreak of
windborne coccidioidomycosis. N Engl J Med 1979; 301:358–61.
Lúquez C, Bianco MI, de Jong LI, et al. Distribution of botulinum toxinproducing clostridia in soils of Argentina. Appl Environ Microbiol
2005; 71:4137–9.
Smith LDS. The occurrence of Clostridium botulinum and Clostridium
tetani in the soil of the United States. Health Lab Sci 1978; 15:74–80.
Hyytiä E, Hielm S, Bjorkroth J, Korkeala H. Biodiversity of Clostridium
botulinum type E strains isolated from ﬁsh and ﬁshery products. Appl
Environ Microbiol 1999; 65:2057–64.

